LRMR · Larimar Therapeutics, Inc.

The thesis

Larimar Therapeutics' only drug, nomlabofusp for Friedreich's ataxia (FA, a rare inherited nerve and muscle disease), still has an open path to FDA accelerated approval, but the shares closed at $2.54 on 28 October 2026 and the confirmatory Phase 3 start remains unconfirmed. The Q3 report, expected around 5 November 2026 (estimate), settles whether the first patient has been dosed and whether the rolling filing is still on schedule for the second half of 2026.

The close of $2.54 is 57.3% below the 52-week high of $5.95, and the shares fell 33.5% over three months (adjusted daily closes, 28 October 2026). The 14-day relative strength index (RSI), a momentum gauge where readings under 30 mark heavy selling, was 45.6, up from 10.8 on 15 October 2026. The close of 15 October 2026 was $1.99, so the shares have recovered part of the October decline.

The narrative is maturing: the regulatory story has been public since the 29 June 2026 first-module submission, and searches of company news through 29 October 2026 found no release after the 29 September 2026 executive appointment. Neither the October fall nor the rebound has a company-announced cause. Nothing new has been reported since the previous note, so the rating stays where it was.

Bullish and bearish views on Larimar Therapeutics, Inc.

The bull case on Larimar Therapeutics, Inc. (LRMR), in brief: The regulatory path remains open. The bear case: The Phase 3 start is unconfirmed.

Bull case

• The regulatory path remains open. Larimar submitted the first module of a rolling Biologics License Application (BLA) on 29 June 2026. The 4 August 2026 update said completion is guided for the second half of 2026 and a mid-2027 launch is targeted if approved.
• Open-label data show a measured benefit. The 4 August 2026 update reported more than 10,000 doses and a 2.6-point improvement on the modified Friedreich's Ataxia Rating Scale at one year against a natural-history comparison group. The study has no placebo arm.
• Cash covers the next milestones. Larimar held $156.3 million in cash, cash equivalents and marketable securities at 30 June 2026 and guided runway into Q3 2027 (Q2 2026 company release, 4 August 2026). The Q2 net loss was $32.8 million.
• Analyst targets sit far above the price. MarketBeat's consensus target was $11.86 on 25 September 2026, LifeSci Capital's Buy rating carried a $25 target on 28 September 2026, and Leerink Partners raised its target to $13 from $12 on 14 September 2026. These targets pre-date the October decline.
• Insider and management signals. A director bought 50,000 shares for about $166,500 on 8 July 2026 (SEC Form 4). Larimar named John B. Harlow Jr., formerly chief commercial officer at Esperion, president and chief operating officer on 29 September 2026.

Bear case

• The Phase 3 start is unconfirmed. Larimar guided first-patient dosing in the confirmatory trial to Q3 2026 in its 4 August 2026 update. Q3 ended on 30 September 2026, and searches of company news through 29 October 2026 found no dosing announcement.
• The October decline has no announced cause. The close fell from $2.96 on 2 October 2026 to $1.99 on 15 October 2026. No company release explains the move, so the partial recovery to $2.54 carries no confirmed information either.
• Anaphylaxis is the central safety issue. Ten of 43 open-label participants had anaphylaxis and discontinued, per the 4 August 2026 update. A boxed warning, a risk-management program or mandatory premedication in the label would narrow the treatable population.
• Single asset, with a financing need ahead. Common shares outstanding rose from 83.1 million at 31 December 2025 to 103.9 million at 30 June 2026 (Q2 2026 balance sheet). Cash runs into Q3 2027 against a mid-2027 launch target, so another equity raise before revenue is possible.

Price setup

The adjusted close of $2.54 on 28 October 2026 sits between the $1.99 close of 15 October 2026 and the $2.96 close of 2 October 2026. The 52-week high is $5.95. The previous note's $1.70 invalidation level lies below the current price and has not been tested.

Crowding evidence is limited. The RSI of 45.6 is neutral, the shares trade well below any prior high, and no insider sales or new share issuance have been reported since the previous note. The one imminent event is the Q3 report, which is the main source of price risk in the next 30 days.

Catalysts, next 30 days

• ~5 November 2026 (est.): Q3 2026 financial and business update. A third-party calendar estimates 6 November 2026 before the open; Larimar has not confirmed a date. The report would show Phase 3 first-patient status, the cash balance and whether BLA completion is still guided for the second half of 2026.
• 31 December 2026: end of the guided half-year for completing the rolling BLA. This falls outside the 30-day window but frames the November report. Completion would resolve the submission milestone and would not establish FDA acceptance.

What would change the view

The case breaks if Larimar moves completion of the rolling BLA beyond the second half of 2026, if the FDA issues a refuse-to-file letter, or if the Q3 report shows the confirmatory Phase 3 has not dosed a patient and gives no new date. A new anaphylaxis case in a premedicated participant, or disclosure of boxed-warning discussions, would also weaken it. A daily close below $1.70, under the October low close of $1.99, would end the price case.

A dosed Phase 3 patient, a confirmed BLA completion timeline and no financing in the Q3 10-Q would strengthen the case. This view is wrong if the report shows all three and the shares still fall below $1.70.

What it trades with

Larimar trades on its own regulatory milestones, not on sector flows. No theme currently carries the name. Broader small-cap biotech funding conditions affect the cost of any equity raise. Biogen's Skyclarys (omaveloxolone), the approved FA treatment for patients 16 and older, is the commercial reference for the disease.